

REF: MDOL/CS-SE/2024- 25/016

August 13, 2024

To,

Listing Department

BSE Ltd

1st Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001.

Scrip Code: 532637

Listing Department

National Stock Exchange of India Limited

“Exchange Plaza”, 5th Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra (E), Mumbai – 400 051

Symbol: MANGALAM

Sub: Intimation of Outcome of the Board Meeting.

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations).

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Tuesday, August 13, 2024 has *inter-alia* transacted, considered and approved the following businesses:

- Re-appointment of **Shri Govardhan M. Dhoot (DIN: 01240086)** as the Managing Director of the Company, for a period of 3 (three) years with effect from November 1, 2024 to October 31, 2027 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company.
- Re-appointment of **Shri Brijmohan M. Dhoot (DIN: 01046420)** as the Whole-time Director of the Company, for a period of 3 (three) years with effect from August 14, 2024 to August 13, 2027 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company.

Details as required under Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 are hereto annexed and marked as **Annexure - I** and **Annexure – II**.

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

- The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended June 30, 2024 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as **Annexure - III.**)

The Board Meeting commenced at 05:00 P.M. and concluded at 07:30 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For **Mangalam Drugs & Organics Limited**

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

Disclosure details in relation to re-appointment of Shri Govardhan M. Dhoot, Managing Director of the Company

Details of events that needs to be provided	Information of such event(s)
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	On the basis of recommendation of the Nomination and Remuneration Committee, the Board of Directors in its meeting held today re-appointed Shri. Govardhan M. Dhoot (DIN: 01240086), as the Managing Director of the Company for a period of 3 (three) years with effect from November 1, 2024 to October 31 2027 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company
Date of appointment/re-appointment/cessation (as applicable) and term of appointment/re-appointment	Date of Re-appointment – Term - 3 Years commencing from 1st November 2024 to 31st October 2027 (both days inclusive)
Brief Profile (in case of appointment)	Shri Govardhan M. Dhoot has over 40 + years of business leadership experience, leading business in manufacturing API sectors. He is serving as Managing Director since past many years. He has completed his bachelor's degree in commerce.
Disclosure of relationships between directors (in case of appointment of a director)	Shri Govardhan M. Dhoot is the brother of Shri Brijmohan M. Dhoot, Whole Time Director of the Company.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Shri Govardhan M. Dhoot is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Annexure II

Disclosure details in relation to re-appointment of Shri Brijmohan M. Dhoot, Whole-time Director of the Company

Details of events that needs to be provided	Information of such event(s)
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	On the basis of recommendation of the Nomination and Remuneration Committee, the Board of Directors in its meeting held today re-appointed Shri. Brijmohan M. Dhoot (DIN: 01046420), as the Whole-time Director of the Company for a period of 3 (three) years with effect from August 14, 2024 to August 13 2027 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company.
Date of appointment/re-appointment/cessation (as applicable) and term of appointment/re-appointment	Date of Re-appointment – Term - 3 Years commencing from August 14, 2024 to August 13, 2027 (both days inclusive).
Brief Profile (in case of appointment)	Shri Brijmohan M. Dhoot has over 40 + years of experience Manufacturing sectors. He is serving as Whole-time Director since five plus years. He has completed his bachelor's degree in commerce.
Disclosure of relationships between directors (in case of appointment of a director)	Shri Brijmohan M. Dhoot is the brother of Shri Govardhan M. Dhoot, Managing Director of the Company.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Shri Brijmohan M. Dhoot is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.